ClinicalTrials.gg
CompletedNCT04560881Updated Jan 12, 2022

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

A Phase 3 interventional study of Inactivated SARS-CoV-2 vaccine (Vero cell) and Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine in COVID-19 Virus Infection, sponsored by Laboratorio Elea Phoenix S.A.. Completed at 4 sites in Argentina. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by Laboratorio Elea Phoenix S.A. · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing Inactivated SARS-CoV-2 Vaccine in COVID-19 — 1 open to participants now, 4 under way, 2 of them phase 3. Inactivated SARS-CoV-2 Vaccine · COVID-19.

Enrollment
6th of 19
3,000 · median 400
Started
2020
with 1 other
Phase 3
8 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
1 of 19
Laboratorio Elea Phoenix S.A.

Among the 19 studies testing Inactivated SARS-CoV-2 Vaccine in COVID-19, this one is the 6th largest by enrollment, is one of 2 that started in 2020, is one of 8 in phase 3, and was the 2nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 19 studies testing Inactivated SARS-CoV-2 Vaccine in COVID-19 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Inactivated SARS-CoV-2 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Inactivated SARS-CoV-2 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged between 18 and 85 years old.

Read the detailed description

SARS-CoV-2 belongs to β Coronavirus family and is a pathogen that can spread across races and is easy to cause respiratory diseases.

In December 2019, patients with pneumonia of unknown causes showed fever, cough, dyspnea, accompanied by medical imaging change of patchy diffuse infiltration of the lungs [2]. Through genome sequencing and analysis of lower respiratory tract alveolar lavage fluid samples from patients with pneumonia of unknown cause, a novel coronavirus different from any known virus was found. The World Health Organization WHO named the virus 2019 novel coronavirus, or 2019-nCoV for short, and the disease caused by the virus was named COVID-19. WHO listed the epidemic as a public health emergency of international concern.

With the spread of the SARS-CoV-2 epidemic in the world, vaccines have become the best weapon for epidemic prevention and control. At present, no vaccine to prevent coronavirus disease (COVID-19) in 2019 has been approved for listing. Based on the experience accumulated in the research and development of coronavirus vaccines in the past, the target of vaccines is also mainly focused on S protein.

Inactivated Virus Vaccine inactivates the virus obtained by culture by heating or chemical methods. The inactivated virus loses its pathogenicity and retains the main antigenic characteristics of the virus capsid, which can stimulate the specific immune response of human body. The inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying, and adding aluminum hydroxide adjuvant. After inoculating the vaccine, the recipients can produce immune response to prevent diseases caused by SARS-CoV-2. The inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying, and adding aluminum hydroxide adjuvant. After inoculating the vaccine, the recipients can produce immune response to prevent diseases caused by SARS-CoV-2.

03

Conditions studied

  • COVID-19 Virus Infection

Browse trials for

Keywords

  • COVID-19
  • SARS-CoV-2 infection
  • Inactivated SARS-CoV-2 Vaccine
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects aged between 18 and 85 years old.
  • By asking for medical history and physical examination, the investigator judged that the health condition is well.
  • Female subjects of childbearing age are not nursing or pregnant at the time of enrolment (negative urine pregnancy test) and have no family planning within the first 3 months after enrolment. Effective measures have been taken within 2 weeks before inclusion.
  • During the whole follow-up period of the study, be able and willing to complete the whole prescribed study plan.
  • With self-ability to understand the study procedures, the \& voluntarily sign an informed consent form and be able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Active Sars-Cov-2 Infection measured by RT-qPCR
  • Has a history of SARS, MERS infection (self-report, on-site inquiry)
  • Has clinical manifestation of fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination.
  • Body temperature > 37.0 ℃ before vaccination
  • Urine pregnancy test positive;
  • Previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated SARS-CoV-2 vaccine have occurred.
  • Has a history of convulsion, epilepsy, encephalopathy or mental illness or family history.
  • With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
  • With severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases.
  • Has been diagnosed with congenital or acquired immune deficiency, infection, lymphoma, leukemia, or other diseases.
  • With known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors.
  • Has a history of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation disease)
  • Receiving anti-TB therapy.
  • Patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days)
  • Inoculated within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination.
  • Received blood products within 3 months before this vaccination
  • Received other research drugs within 6 months before this vaccination.
  • Other circumstances judged by investigators that are not suitable for this clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
3,000 participants (actual)

Study arms

  • Experimental
    Inactivated SARS-CoV-2 vaccine, manufactured by BIBP

    Intramuscular injection

    Biological: Inactivated SARS-CoV-2 vaccine (Vero cell)

  • Placebo comparator
    Placeboof Inactivated SARS-CoV-2 vaccine, manufactured by BIBP

    Intramuscular injection

    Biological: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine

Interventions

  • BiologicalInactivated SARS-CoV-2 VaccineStudies of Inactivated SARS-CoV-2 VaccineInactivated SARS-CoV-2 Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.

  • BiologicalPlacebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine

    Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.

06

What researchers measure

Primary outcomes

  1. Incidence of COVID-19 cases after two-doses of vaccination

    All confirmed COVID -19 cases 14 days after the full course of vaccination among healthy population aged between 18 and 85 years old.

    Time frame: 14 days after the full course of vaccination

Secondary outcomes

  1. The 4-fold increase rate of anti-SARS-CoV-2 neutralizing antibody

    Time frame: 14 days after 2-dose of immunization and 28 days after full course of immunization

  2. The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody

    Time frame: 14 days after 2-dose of immunization and 28 days after full course of immunization

  3. The Geometric Mean Increase (GMI) of anti-SARS-CoV-2 neutralizing antibody

    Time frame: 14 days after 2-dose of immunization and 28 days after full course of immunization

  4. Incidence of any adverse reactions/events

    Time frame: Within 30 minutes after each dose of vaccine

  5. Incidence of adverse reactions/events

    Time frame: 0 ~ 21/28 days after each dose of vaccine

  6. Incidence of serious adverse events (SAE)

    Time frame: From the beginning of the first dose to 12 months after the whole course of immunization

Other outcomes

  1. Anti-SARS-CoV-2 neutralizing antobody (NtAb) (immunological surrogate endpoint)

    The protective level of Anti-SARS-CoV-2 NtAbs

    Time frame: 14 days after 2-dose of immunization.

07

Study locations

4 sites
  • Fundación Huésped
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1202ABB, Argentina
  • Vacunar Liniers
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1408FVD, Argentina
  • Vacunar Cañitas
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426BOF, Argentina
  • Vacunar Coghlan
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1430BKB, Argentina
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2021, 14 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 23, 2020
StartActual
Sep 16, 2020
Primary completionActual
Dec 13, 2021
CompletionActual
Dec 13, 2021
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04560881
Lead sponsor
Laboratorio Elea Phoenix S.A.
Collaborators
Beijing Institute of Biological Products Co Ltd., China National Biotec Group Company Limited, Fundación Huésped
Responsible party
Sponsor
First posted
Sep 23, 2020
Start date
Sep 16, 2020
Primary completion
Dec 13, 2021
Completion
Dec 13, 2021
Last update
Jan 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inactivated SARS-CoV-2 Vaccine

Start the discussion